SCHEMBL6337882

SCHEMBL6337882

NCCCNS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
PKM P14618 2/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
LMNA P02545 1/20 0.55
SOS1 Q07889 1/20 0.53
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
TAAR1 Q96RJ0 1/20 0.49
HTR1A P08908 1/20 0.48
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
HTR7 P34969 1/20 0.48
CYP3A4 P08684 1/20 0.47
HDAC3 O15379 2/20 0.47
HDAC1 Q13547 2/20 0.47
CA12 O43570 4/20 0.47
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
MMP2 P08253 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15145890 0.91 ALDH1A1 (0.77) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL18392112 0.82 CYP3A4 (0.68) ALDH1A1PKMLMNACYP3A4CA12
SCHEMBL10029061 0.82 MMP2 (0.63) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL10029067 0.81 MMP2 (0.64) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL10029063 0.81 MMP2 (0.64) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL8970754 0.81 ALDH1A1 (0.70) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL4516002 0.81 TAAR1 (0.70) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL15145805 0.80 ALDH1A1 (0.81) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL6236938 0.76 SIGMAR1 (0.63) ALDH1A1PKMMEN1KMT2ASMN1; SMN2
SCHEMBL3277847 0.74 ALDH1A1 (0.77) ALDH1A1PKMMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1207289-C Metalloprotease inhibitors, pharmaceutical compositions containing them and their use as medicaments, process and intermediates for their preparation AGOURON PHARMA (US) 2005-06-22 CN disclosed
US-6849732-B2 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation AGOURON PHARMACEUTICALS, INC. (US) 2005-02-01 US disclosed
EP-1095936-B1 Intermediates useful for the preparation of metallproteinase inhibitors AGOURON PHARMA (US) 2004-11-24 EP disclosed
CN-1542002-A Inhibitors of metalloproteinase, pharmaceutical compositions containing them, their pharmaceutical application and methods and intermediate compounds for their preparation ������ҩ�����޹�˾ 2004-11-03 CN disclosed
US-20030130506-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation AGOURON PHARMACEUTICALS, INC. (US) 2003-07-10 US disclosed
US-6500948-B1 SUCH AS N-HYDROXY-4-(4-((PYRID-4-YL)OXY)BENZENESULFONYL)-2,2-DIMETHYL-TETRAHYDRO-2H -1,4-THIAZINE-3-CARBOXYLIC ACID AGOURON PHARMACEUTICALS, INC. 2002-12-31 US disclosed
EP-1095936-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation AGOURON PHARMACEUTICALS, INC. (US) 2001-05-02 EP disclosed
US-6153757-A A PRODRUG, SALT OR SOLVATE AS ANTITUMOR AGENT AND ENZYME INHIBITOR FOR INHIBITING METALLOPROTEINASES, TUMOR NECROSIS FACTOR AGOURON PHARMACEUTICALS, INC. (US) 2000-11-28 US disclosed
CN-1207734-A Metalloprotease inhibitors, pharmaceutical compositions containing them and their use as medicaments, process and intermediates for their preparation AGOURON PHARMA (US) 1999-02-10 CN disclosed
EP-0874830-A1 METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION AGOURON PHARMACEUTICALS, INC. (US) 1998-11-04 EP disclosed
WO-1997020824-A1 METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION AGOURON PHARMACEUTICALS, INC. (US) 1997-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130506-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation MMP9, MMP3, MMP2 ALDH1A1 595/4885PKM 2203/4885MEN1 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.